2 unchanged sentences
Our policy governing transactions in our securities by our directors, officers, and employees permits our officers, directors and employees to enter into trading plans complying with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
−Removed: As disclosed in the table below, during the third quarter of 2023, certain of our executive officers and directors adopted a “Rule 10b5-1 trading arrangement”.
+Added: As disclosed in the table below, during the first quarter of 2024, certain directors adopted a “Rule 10b5-1 trading arrangement”.
These plans provide for the sale of our common stock and are intended to satisfy the affirmative defense in Rule 10b5-1(c).
1 unchanged sentence
Maximum Total Shares of Common Stock to be Sold Under the Plan (2)
−Removed: Ryan Watts, Ph.D.
−Removed: Chief Executive Officer
3/21/2024 7/1/2025 30,720
−Removed: Alexander Schuth, M.D.
−Removed: Chief Operating and Financial Officer
−Removed: 9/29/2023 2/14/2025 116,918
−Removed: Carole Ho, M.D.
−Removed: Chief Medical Officer
+Added: Jennifer Cook
3/1/2024 6/3/2025 1,458
1 unchanged sentence
(1) In each case, the trading arrangement may expire on an earlier date if and when all transactions under the arrangement are completed.
−Removed: (2) These amounts represent the maximum total shares that could be sold under the plan, but the amounts may change for executive officers due to the sale of shares to satisfy tax withholding requirements.
−Removed: No other officers or directors, as defined in Rule 16a-1(f), adopted and/or terminated of a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” as defined in Regulation S-K Item 408, during the third quarter ended September 30, 2023.
+Added: (2) This amount represents the maximum total shares that could be sold under the plan, but the amounts may change for executive officers due to the sale of shares to satisfy tax withholding requirements.
+Added: No other officers or directors, as defined in Rule 16a-1(f), adopted and/or terminated of a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” as defined in Regulation S-K Item 408, during the first quarter ended March 31, 2024.
EXHIBIT INDEX
2 unchanged sentences
Number Filing Date
+Added: Form of P re- F und ed W arrant
+Added: — — — Filed herewith
31.1 Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act.
6 unchanged sentences
— — — Furnished herewith
−Removed: Amendment to Definitive LRRK2 Agreement and Waiver of and Amendment to Right of First Negotiation, Option, and License Agreement.
−Removed: — — — Filed herewith
101.INS XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Incline XBRL document — — — Furnished herewith
9 unchanged sentences
— — — Furnished herewith
−Removed: 104 The cover page from the Company's Quarterly Report on Form 10-Q for the three months ended September 30, 2023, formatted in Inline XBRL (contained in Exhibit 101)
+Added: 104 The cover page from the Company's Quarterly Report on Form 10-Q for the three months ended March 31, 2024, formatted in Inline XBRL (contained in Exhibit 101)
— — — Furnished herewith
1 unchanged sentence
under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing.
−Removed: # Certain information has been excluded from this exhibit because it is both not material and would likely cause competitive harm to the registrant if publicly disclosed.
−Removed: Omissions are designated as [***].
+Added: # Portions of this exhibit have been omitted pursuant to a request for confidential treatment and this exhibit has been filed separately with the SEC.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
DENALI THERAPEUTICS INC.
−Removed: November 7, 2023 By:
+Added: May 7, 2024 By:
President and Chief Executive Officer
(Principal Executive Officer)
−Removed: November 7, 2023 By:
+Added: May 7, 2024 By:
/s/ Alexander O.
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.